info@seagull-health.com
SeagullHealth
语言:
search
new
Indications of Perfluorohexyl Octane Eye Drops (Miebo)
501
Article source: Seagull Pharmacy
Nov 11, 2025

Perfluorohexyl Octane Eye Drops (Miebo) is a new ophthalmic therapeutic drug approved by the U.S. Food and Drug Administration (FDA) in 2023, providing an innovative treatment option for patients with dry eye disease.

Indications of Perfluorohexyl Octane Eye Drops (Miebo)

Targeted Treatment for Dry Eye Disease

Perfluorohexyl Octane Eye Drops are specifically used to treat the signs and symptoms of dry eye disease.

This drug has been verified through rigorous clinical trials and is mainly intended for patient populations with a history of dry eye disease and accompanying clinical symptoms of meibomian gland dysfunction.

Specifications and Properties of Perfluorohexyl Octane Eye Drops (Miebo)

Basic Physical Properties

Perfluorohexyl Octane Eye Drops are a sterile, clear and colorless ophthalmic solution, with the active ingredient content being 100% perfluorohexyl octane.

The chemical name of this semifluorinated alkane is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane.

Molecular Structure Characteristics

The molecular formula of the active ingredient is C₁₄H₁₇F₁₃, and its molecular weight is 432.26 g/mol.

In terms of physicochemical properties, perfluorohexyl octane is almost immiscible with water, but it is miscible with ethanol and most organic solvents.

Packaging Specifications

Each multi-dose bottle contains 3 mL of perfluorohexyl octane, with a density of 1.338 g/mL, presenting as a clear and colorless liquid.

The drug is packaged in a 5 mL polypropylene bottle for multiple uses, equipped with a dropper tip and a screw cap.

Storage Methods of Perfluorohexyl Octane Eye Drops (Miebo)

Temperature Control Requirements

Perfluorohexyl Octane Eye Drops should be stored at a temperature of 15ºC to 25ºC (59ºF to 77ºF).

This storage temperature range ensures that the drug maintains stability and therapeutic efficacy throughout its shelf life.

Usage Period After Opening

After the drug bottle is opened, the drug can continue to be used within the expiration date marked on the bottle.

Proper Storage Practices

To ensure the quality of the drug, it should be stored away from extreme temperature environments, including freezing or exposure to high-temperature conditions.

At the same time, the bottle cap should be kept tightly closed to prevent contamination and evaporation.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in 2023. Its unique evaporation-inhibiting effect provides a new option for patients with dry eye syndrome.How to Purch...
Precautions for Wayrilz (Rezabrutinib) Administration
Wayrilz (Rezabrutinib) is a Bruton's Tyrosine Kinase inhibitor, first approved in the United States in 2025. It is primarily indicated for the treatment of persistent or chronic immune thrombocyto...
What Are the Side Effects of Wayrilz (Rezabrutinib)?
Wayrilz (Rezabrutinib) is an oral Bruton's Tyrosine Kinase inhibitor. Approved by the U.S. FDA in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopenia in adults...
How to Purchase Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel Bruton's Tyrosine Kinase (BTK) inhibitor. Approved in the United States in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopeni...
How to Use Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a semifluorinated alkane ophthalmic solution. It was first approved in the United States in 2023 and is specifically used to treat the signs and symptoms of ...
Precautions for Using Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new type of semifluorinated alkane eye drops. Approved in the United States in 2023, it is specifically used to treat the signs and symptoms of dry eye dis...
What Are the Side Effects of Perfluorohexyl Octane Eye Drops (Miebo)?
Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in the United States in 2023, with its active ingredient being 100% perfluorohexyl octane.What Are the Side Effects of ...
How to Purchase Cobenfy (KarXT)
Cobenfy (KarXT) is a new antipsychotic drug approved in 2024. Its dual mechanism of action provides a new option for patients with schizophrenia. As a strictly controlled prescription drug, standardiz...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved